Answers are grounded in this paper and cite their sources.
TARE using SIR-Spheres may achieve similar TTD in QOL compared with atezolizumab-bevacizumab, as the analyses found no statistically significant differences between these two interventions. Both TARE using SIR-Spheres and atezolizumab-bevacizumab seem to be more efficacious than sorafenib in maintaining QOL.
No takes yet. Share an insight, caveat, or question.
Agirrezabal et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: